Loading stock data…
Celldex Therapeutics, Inc. (CLDX)
$37.44+2.18 (+6.18%)
Market ClosedLast close Jun 29
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celldex Therapeutics, Inc. in the Healthcare sector is trading at $37.44 with a market capitalization of $2.3B. Wall Street consensus targets $57.53 (15 analysts), implying a +53.7% move over the next 12 months. The stock is currently near its 52-week high of $37.54, remaining 32.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15,000↓ | $121,000 | $0↓ | $730,000↑ | $695,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$84.44M↑ | -$87.15M↓ | -$73.62M↓ | -$63.86M↓ | -$62.74M |
| Net Income | -$78.69M↑ | -$81.32M↓ | -$67.04M↓ | -$56.60M↓ | -$53.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.17%
Volume
Today's trading volume
1.53M
Recent News
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight. Read that last number again. This stock nearly doubled in a single session. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, I could just tell you “wow, what a move” and carry on with my day. But that’s not what I do, and it’s not wh
Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum
Celldex Therapeutics (CLDX) has attracted fresh attention after a recent move in its share price, with the stock closing at US$31.27 and showing mixed short term performance over the past week and month. See our latest analysis for Celldex Therapeutics. The recent 1 day share price return of 4.37% and 7 day share price return of 9.26% sit against a year to date share price return of 15.77% and a 1 year total shareholder return of 47.08%. This points to momentum that has picked up again after...
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals
Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawing investor attention after recent trading left the stock at a last close of US$32. With no single headline event driving sentiment, the focus turns to its fundamentals. See our latest analysis for Celldex Therapeutics. Recent moves put Celldex on a softer footing in the very near term, with the 7 day share price return down 5.49%, but a 90 day share price return of 30.08% and 1 year total shareholder return of...
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?